Filtered By:
Condition: Heart Attack
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 128 results found since Jan 2013.
Cardiovascular comorbidities in atopic dermatitis: Potential implications for the use of Janus kinase inhibitors
To the Editor: The Food and Drug Administration recently approved the use of 2 oral Janus kinase (JAK) inhibitors —abrocitinib and upadacitinib—for patients with moderate-to-severe atopic dermatitis (AD) not adequately controlled with systemic therapies, including biologics, or when the use of such treatments is inadvisable.1,2 In September 2021, the Food and Drug Administration issued a boxed warning for a ll JAK inhibitors regarding the increased risk of serious infections, heart attack, stroke, cancer, blood clots, and death.
Source: Journal of the American Academy of Dermatology - August 19, 2023 Category: Dermatology Authors: J. Mark Jackson, Amanda Althoff, Lawrence Rasouliyan, Stacey Long, Carla L. Zema Tags: Research letter Source Type: research
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week
J Am Coll Cardiol. 2023 Aug 15;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055.ABSTRACTAmong statin-treated patients, inflammation assessed by means of high-sensitivity C-reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all-cause mortality than low-density-lipoprotein cholesterol (LDL-C). Several therapies that target residual inflammatory risk significantly reduce vascular event rates. For coronary artery disease patients already taking guideline-directed medical care, including statins, low-dose colchicine (0.5 mg/d orally) has been shown to safely lower major adverse cardiovascular even...
Source: Atherosclerosis - August 9, 2023 Category: Cardiology Authors: Kyle Nelson Valentin Fuster Paul M Ridker Source Type: research
Testosterone Treatments Aren ’ t Linked to Heart Risks When Patients Are Carefully Monitored, Study Finds
Advertisements for treatments for “low T,” or low testosterone levels in middle-aged and older men, have led to spikes in demand. But the safety and legitimacy of those testosterone therapies hasn’t been clear.
In a new study published in the New England Journal of Medicine and presented at the Endocrine Society’s annual meeting, researchers provide the most conclusive evidence yet that testosterone treatments appear to be safe for the heart and are not associated with an increased risk of certain heart-related events.
In the study, led by researchers at the Cleveland Clinic, more than 5,200 men age...
Source: TIME: Health - June 16, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate heart health Source Type: news
Plain language summary of results from ORION-10 and ORION-11: Two studies to learn how well inclisiran works in people with high cholesterol
Future Cardiol. 2023 Jun 6. doi: 10.2217/fca-2022-0133. Online ahead of print.ABSTRACTWHAT IS THIS PLAIN LANGUAGE SUMMARY ABOUT?: This is a summary of the article describing the results of the ORION-10 and ORION-11 studies, which was published in the New England Journal of Medicine in April 2020. The studies included adult participants with atherosclerotic cardiovascular disease (ASCVD). ASCVD happens when the blood vessels that carry blood from the heart to other areas of the body are blocked by fatty build-up (plaque) causing a heart attack, stroke, or other problems. High levels of low-density lipoprotein cholesterol (L...
Source: Atherosclerosis - June 7, 2023 Category: Cardiology Authors: Kausik K Ray R Scott Wright Source Type: research
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
FDA Approves New Menopause Drug for Hot Flashes
WASHINGTON — U.S. health regulators on Friday approved a new type of drug for women dealing with uncomfortable hot flashes caused by menopause.
The Food and Drug Administration approved the once-a-day pill from Astellas Pharma to treat moderate-to-severe symptoms, which can include sweating, flushing and chills.
Astellas’ drug, Veozah, uses a new approach, targeting brain connections that help control body temperature. The FDA said the medication will provide “an additional safe and effective treatment option for women,” in a statement.
More than 80% of women experience hot flashes during menopause,...
Source: TIME: Health - May 15, 2023 Category: Consumer Health News Authors: Matthew Perrone/AP Tags: Uncategorized Drugs healthscienceclimate wire Source Type: news
Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota.
Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research
New Nasal Spray for Migraines Approved by FDA
MONDAY, March 13, 2023 – Migraine sufferers will soon have a new treatment option that works more quickly and may be safer for people at risk of heart attack or stroke.
The U.S. Food and Drug Administration has approved Pfizer Inc.’s zavegepant...
Source: Drugs.com - Daily MedNews - March 13, 2023 Category: General Medicine Source Type: news
New Nasal Spray for Migraines, Zavzpret, Approved by FDA
MONDAY, March 13, 2023– Migraine sufferers will soon have a new treatment option that works more quickly and may be safer for people at risk of heart attack or stroke.
The U.S. Food and Drug Administration has approved Pfizer Inc.’s...
Source: Drugs.com - Daily MedNews - March 13, 2023 Category: General Medicine Source Type: news
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Here ’s an Alternative to Statins for Lowering Cholesterol
Statins have revolutionized heart disease by lowering cholesterol effectively—by up to 50% or more. But anywhere from 7% to 29% of people who take them may be more susceptible to its side effects, which include weakening of muscles and pain, and decide they can’t tolerate them. In a recent study published in JAMA Network Open, for example, researchers at Brigham and Women’s Hospital reported that more than 20% of patients seen at the hospital from 2000 to 2018 who were recommended to take statins refused to take them, and those who refused took three times as long to lower their LDL cholesterol to target ...
Source: TIME: Health - March 4, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate heart health Source Type: news
Reply: Association between triple therapy and major adverse cardiovascular events in COPD patients
We thank P. Almagro and P. Martinez-Camblor for their interest in our work and for their salient comments. While we agree that there is no universally accepted definition of major adverse cardiovascular event (MACE), the US Food and Drug Administration (FDA) and the European Medicines Agency include nonfatal myocardial infarction and stroke as well as cardiovascular (CV) mortality in their MACE definition [1]. Importantly, this definition includes both haemorrhagic and ischaemic stroke [1–4]. In our study, we followed this classical "three-point" definition of MACE (including haemorrhagic strokes). While this definit...
Source: European Respiratory Journal - March 2, 2023 Category: Respiratory Medicine Authors: Yang, M.-J., Guo, S.-L., Sin, D. D. Tags: Correspondence Source Type: research
What to Know if Your Doctor Put You on Statins to Lower Cholesterol
High cholesterol is a prime example of having too much of a good thing. Our bodies naturally make this substance in the liver and then transport it throughout the body for multiple functions, including hormone regulation, cell tissue regeneration, and vitamin absorption. When the system is working well, cholesterol can boost overall health. But when a certain type called low-density lipoprotein—LDL, sometimes dubbed the “bad” kind—is overproduced, not only does it block the “good” kind called high-density lipoprotein (HDL), but it can also begin to accumulate in the arteries and form thi...
Source: TIME: Health - January 25, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news
How AI Is Changing Medical Imaging to Improve Patient Care
That doctors can peer into the human body without making a single incision once seemed like a miraculous concept. But medical imaging in radiology has come a long way, and the latest artificial intelligence (AI)-driven techniques are going much further: exploiting the massive computing abilities of AI and machine learning to mine body scans for differences that even the human eye can miss.
Imaging in medicine now involves sophisticated ways of analyzing every data point to distinguish disease from health and signal from noise. If the first few decades of radiology were about refining the resolution of the pictures taken of...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Alice Park and Video by Andrew D. Johnson Tags: Uncategorized Frontiers of Medicine 2022 healthscienceclimate Innovation sponsorshipblock Source Type: news
Telmisartan and Walking Performance in Peripheral Artery Disease
Lower extremity peripheral artery disease (PAD) is a morbid manifestation of atherosclerosis that affects an estimated 230 million people worldwide. In the context of an aging population and the increasing rates of diabetes, the prevalence of PAD is expected to increase. Patients with PAD, by virtue of having atherosclerosis, have a heightened risk of myocardial infarction and stroke; thus reducing these risks has been the primary focus of most medical interventions. Although these efforts are warranted, recent evidence has broadened awareness that the dominant morbidity involves the limbs, including functional impairment ...
Source: JAMA - October 4, 2022 Category: General Medicine Source Type: research
